Procalcitonin (PCT) is a peptide precursor of the hormone calcitonin, and belongs to calcitonin (CT) superfamily of peptides. Procalcitonin is a 116 amino acid peptide that has an apparent molecular weight of 14.5 kDa. It can be segregated into three parts, namely immature calcitonin, calcitonin carboxyl terminus peptide-1, and amino terminus of the PCT region. Procalcitonin was first classified by Bernard Roos and Leonard J. Deftos in the early 1970s. Procalcitonin is produced by C cells of the thyroid and endocrine cells of the lung. In human body, level of unprocessed procalcitonin rises extensively after shock, injury or bacterial infection, which increases the production of procalcitonin in the body.
Click To Continue Reading On Procalcitonin Antibody Market
This might lead to organ dysfunction and call for immediate treatment of the patient. The level of procalcitonin in the body can be diagnosed with wet lab analysis using procalcitonin antibody. On the basis of antibody type, the procalcitonin antibody market is segmented into polyclonal procalcitonin antibody and monoclonal procalcitonin antibody. For instance, according to the World Health Organization (WHO) fact sheet of 2018, cancer was responsible for 8.8 million deaths in 2015 globally. Moreover, according to the World Health Organization report of 2017, around 1.0 million deaths occurred due to HIV related illnesses worldwide. Furthermore, WHO 2017, fact sheet revealed that 71 million people were having chronic hepatitis C infection. Approximately 399,000 people each year from hepatitis C,
These incidences have led to the adoption of new techniques and procedures by research institutes and hospitals for quick diagnosis of the diseases, so that it can be treated within the earliest time frame. In addition, increasing funding for research and development by the marketplace for the development of efficient, safer, and innovative products for the treatment of diseases as cancer is fueling growth of the procalcitonin antibody market. For instance, in 2018, the US government approved $ 3 billion funds for the National Institutes of Health research and development activities.
Geriatric population is expected to exhibit significant growth in the procalcitonin antibody market, followed by Europe. According to the Center for Strategic and International Studies, in 2015, 9.5% of the population in China was 65 years or older and as long as the United Nations, it is projected to reach 27.5% by 2050.
Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1907
Key vendors:
bioMerieux, HyTest, Roche Diagnostics, Snibe, Thermo Fisher Scientific, Vazyme Biotech, Hotgen Biotech, Getein Biotech, and Hangzhou Realy Tech Co., Ltd.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through emerging market trends, technologies, and potential absolute dollar opportunities.
Mr. Shah
Coherent Market Insights
1001 4th Ave, # 3200
Seattle, WA 98154
Tel: + 1-206-701-6702 Email: sales@coherentmarketinsights.com
Visit our news site: https://www.coherenttimes.org/